Multiple Myeloma Clinical Trials in United Kingdom

A listing of 23 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

United Kingdom

Multiple Myeloma

13 - 23 of 23

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 23 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are .

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Recruiting

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/26/2025

Locations: University of Arkansas, Little Rock, Arkansas +108 locations

University of Arkansas, Little Rock, Arkansas

City of Hope, Duarte, California

UC San Diego Health Moores Cancer Center, San Diego, California

University of California San Francisco (UCSF), San Francisco, California

Stanford University, Stanford, California

Moffitt Cancer Center, Tampa, Florida

Emory University Hospital, Atlanta, Georgia

University of Chicago, Chicago, Illinois

University of Iowa, Iowa City, Iowa

University Of Maryland Medical Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Center, Detroit, Michigan

Mayo Clinic Hospital - Rochester, Rochester, Minnesota

Montefiore M-E Center, Bronx, New York

Mount Sinai Medical Venter, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

University of Rochester, Rochester, New York

Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

The Ohio State University, Columbus, Ohio

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Texas Southwestern Medical Center, Dallas, Texas

University of Virginia, Charlottesville, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Medical College Wisconsin, Milwaukee, Wisconsin

Princess Alexandra Hospital, Brisbane, Not set

Royal Prince Alfred Hospital, Camperdown, Not set

Royal Brisbane and Womens Hospital, Herston, Not set

Alfred Health, Melbourne, Not set

Austin Hospital, Melbourne, Not set

Peter MacCallum Cancer Centre, Melbourne, Not set

Fiona Stanley Hospital, Murdoch, Not set

Calvary Mater Newcastle Hospital, Waratah, Not set

Westmead Hospital, Westmead, Not set

Jules Bordet Instituut, Anderlecht, Not set

UZA, Antwerpen, Not set

UZ Gent, Gent, Not set

UZ Leuven, Leuven, Not set

Cross Cancer Institute, Edmonton, Not set

McMaster University, Hamilton, Not set

Hopital Maisonneuve-Rosemont, Montréal, Not set

Mcgill University Health Centre, Montréal, Not set

Ottawa Hospital Research Institute, Ottawa, Not set

(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, Not set

Princess Margaret Cancer Centre, Toronto, Not set

Vancouver General Hospital, Vancouver, Not set

Fakultni nemocnice Brno, Brno, Not set

Fakultni nemocnice Hradec Kralove, Králová, Not set

Fakutni nemocnice Ostrava, Ostrava, Not set

Fakultni nemocnice Plzen, Plzen, Not set

Vseobecna fakultni nemocnice v Prague, Prague, Not set

CHRU de Lille - Hopital Claude Huriez, Lille, Not set

Hospices Civils De Lyon, Lyon, Not set

CHU De Nantes - Hématologie Clinique, Nantes, Not set

CHU Poitiers - Pôle régional de Cancérologie, Poitiers, Not set

Hopital Saint Louis - Aphp Hôpitaux Universitaires Saint-Louis, Saint-Louis, Not set

CHU de Toulouse, Toulouse, Not set

University Hospital of Cologne, Cologne, Not set

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Not set

University Hospital of Leipzig, Leipzig, Not set

Tübingen, Tübingen, Not set

University Hospital of Würzburg, Würzburg, Not set

Attikon University General Hospital of Attica, Athens, Not set

'G. Papanikolaou' Hospital of Thessaloniki, Thessaloníki, Not set

Hadassah Medical Center, Jerusalem, Not set

Sheba medical center, Ramat Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Juntendo University Hospital, Bunkyō-Ku, Not set

Kyushu University Hospital - Hematology/Oncology, Fukuoka, Not set

Hokkaido University Hospital-Department of Hematology, Hokkaido, Not set

Hyogo College of Medicine, Hyōgo, Not set

Kanazawa University Hospital, Kanazawa, Not set

Nagoya City University Hospital - Department of Hematology & Oncology, Nagoya, Not set

Okayama University Hospital - Hematology/Oncology, Okayama, Not set

Osaka metropolitan university hospital, Osaka, Not set

Japanese Red Cross Medical Center - Hematology, Shibuya, Not set

Keio University Hospital - Hematology, Shinjuku-Ku, Not set

Tohoku University Hospital - Hematology, Tōhoku, Not set

VU Medisch Centrum, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Radboud UMC, Nijmegen, Not set

Erasmus MC, Rotterdam, Not set

UMC Utrecht, Utrecht, Not set

Oslo University Hospital Ullevål - Oncology, Oslo, Not set

Hospital Universitario Germans Trias i Pujol, Badalona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Instituto Catalán de Oncología, Barcelona, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

CLINICA UNIV. DE NAVARRA, Pamplona, Pamplona, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital de Santiago de Compostela, Santiago De Compostela, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Hospital Universitario la Fe, Valencia, Valencia, Not set

Sahlgrenska Universitetssjukhuset, Göteborg, Not set

Landstinget i Ostergotland-Universitetssjukhuset i Linkoping, Linköping, Not set

Skånes University Hospital Lund, Lund, Not set

Akademiska Sjukhuset, Uppsala, Not set

Universitaetsspital Basel - Zentrum fur Hamato-Onkologie, Basel, Not set

Universitaetsspital Bern, Inselspital, Bern, Not set

Centre Hospitalier Universitaire Vaudois (CHUV)Département d'oncologie, Lausanne, Not set

Universitaetsspital Zuerich -Universitaeren Herzzentrum Zuerich, Zürich, Not set

Queen Elizabeth Medical Centre, Birmingham, Not set

University Hospital of Wales, Cardiff, Not set

Conditions: Multiple Myeloma

Learn More ›

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

NCT05768178

Recruiting

This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Cobim... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: University Hospital Birmingham, Birmingham, Not set +14 locations

Conditions: Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic, Solid Tumour

Learn More ›

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597

Recruiting

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/07/2025

Locations: Community Health Network, Indianapolis, Indiana +21 locations

Conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma

Learn More ›

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632

Recruiting

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona +40 locations

Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona

Highlands Oncology Group - Springdale /ID# 267742, Springdale, Arkansas

Rocky Mountain Cancer Centers - Aurora /ID# 268574, Aurora, Colorado

Medical Oncology Hematology Consultants /ID# 268560, Newark, Delaware

Hope And Healing Cancer Services /ID# 268536, Hinsdale, Illinois

Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne, Indiana

Tulane University School of Medicine /ID# 251204, New Orleans, Louisiana

Mayo Clinic - Rochester /ID# 251164, Rochester, Minnesota

NHO Revive Research Institute, LLC /ID# 267869, Lincoln, Nebraska

Mt Sinai /ID# 251166, New York, New York

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167, New York, New York

University of North Carolina /ID# 251203, Chapel Hill, North Carolina

Wake Forest Univ HS /ID# 251165, Winston-Salem, North Carolina

University Of Cincinnati Medical Center /ID# 251746, Cincinnati, Ohio

Willamette Valley Cancer Institute and Research Center /ID# 267088, Eugene, Oregon

Vanderbilt Ingram Cancer Center /ID# 252470, Nashville, Tennessee

Texas Oncology - Central/South Texas /ID# 268563, Austin, Texas

Oncology Consultants /ID# 268323, Houston, Texas

Texas Oncology - Northeast Texas /ID# 268877, Tyler, Texas

Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax, Virginia

Fred Hutchinson Cancer Center /ID# 267940, Seattle, Washington

Northwest Medical Specialties Tacoma /ID# 267117, Tacoma, Washington

Juravinski Cancer Centre /ID# 252053, Hamilton, Ontario

Ottawa Hospital Research Institute /ID# 252151, Ottawa, Ontario

Odense University Hospital /ID# 251261, Odense, Syddanmark

Sygehus Lillebalt, Vejle /ID# 251260, Vejle, Syddanmark

Institut Paoli-Calmettes /ID# 252100, Marseille, Bouches-du-Rhone

Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 252101, Creteil, Paris

CHU de Nantes, Hotel Dieu -HME /ID# 251196, Nantes, Pays-de-la-Loire

HCL - Hopital Lyon Sud /ID# 251223, Pierre Benite CEDEX, Rhone

CHU Poitiers - La miletrie /ID# 251219, Poitiers, Vienne

AP-HP - Hopital Saint-Antoine /ID# 252326, Paris, Not set

The Chaim Sheba Medical Center /ID# 251329, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 251573, Tel Aviv, Tel-Aviv

Hadassah Medical Center-Hebrew University /ID# 252079, Jerusalem, Yerushalayim

Rabin Medical Center /ID# 251330, Petah Tikva, Not set

Hospital Universitario Marques de Valdecilla /ID# 251528, Santander, Cantabria

Hospital Universitario Puerta de Hierro - Majadahonda /ID# 251545, Majadahonda, Madrid

Hospital Universitario de Salamanca /ID# 251529, Salamanca, Not set

University College London Hospital /ID# 251357, London, Greater London

The Christie Hospital /ID# 251774, Manchester, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

NCT05372354

Recruiting

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +16 locations

Conditions: Multiple Myeloma

Learn More ›

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512

Recruiting

The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/28/2025

Locations: Local Institution, Birmingham, Alabama +197 locations

Local Institution, Birmingham, Alabama

Local Institution - 0021, Birmingham, Alabama

Local Institution - 0013, Muscle Shoals, Alabama

Local Institute, Goodyear, Arizona

Local Institution - 0023, Anaheim, California

Local Institution, Anaheim, California

Local Institution - 0045, Burbank, California

Local Institution, Corona, California

Local Institution - 0048, Downey, California

Local Institution - 0052, Fountain Valley, California

Local Institute, Los Angeles, California

Local Institute, Santa Rosa, California

Local Institution - 0051, Santa Rosa, California

Local Institution - 0057, Washington, District of Columbia

Florida Cancer Specialists & Research Institute, Brooksville, Florida

Local Institution, Brooksville, Florida

Local Institution - 0044, Fort Lauderdale, Florida

Local Institution - 0017, Jacksonville, Florida

Local Institution, Jacksonville, Florida

Local Institution - 0046, Savannah, Georgia

Local Institute, Valdosta, Georgia

Local Institution - 0047, Valdosta, Georgia

Local Institution, Skokie, Illinois

Local Institution - 0041, Springfield, Illinois

Local Institution - 0012, Urbana, Illinois

Local Institution - 0058, Anderson, Indiana

Local Institution - 0011, Indianapolis, Indiana

Local Institution, Indianapolis, Indiana

Local Institution - 0061, Des Moines, Iowa

Local Institute, Sioux City, Iowa

Local Institution - 0018, Sioux City, Iowa

Local Institution - 0062, Lexington, Kentucky

Local Institution - 0064, London, Kentucky

Local Institute, Louisville, Kentucky

Local Institution - 0042, Louisville, Kentucky

Cancer Center of Acadiana at Lafayette General Health, Lafayette, Louisiana

Local Institution, Lafayette, Louisiana

Local Institution - 0009, Shreveport, Louisiana

Local Institution, Shreveport, Louisiana

Local Institution, Minneapolis, Minnesota

Local Institution - 0030, Woodbury, Minnesota

Local Institution - 0059, Jackson, Mississippi

Local Institute, Southaven, Mississippi

Local Institute, Kansas City, Missouri

Local Institution - 0050, Kansas City, Missouri

Local Institution - 0037, Missoula, Missouri

Local Institute, Saint Joseph, Missouri

Local Institution - 0015, Saint Louis, Missouri

Local Institution, Saint Louis, Missouri

Local Institution - 0020, Springfield, Missouri

Local Institution, Springfield, Missouri

Local Institute, Missoula, Montana

Local Institution - 0060, Lincoln, Nebraska

Local Institute, Omaha, Nebraska

Local Institution - 0024, Omaha, Nebraska

Local Institution - 008, Does Not Exist, New Jersey

Generic Country - Canada, No City Provided, New Jersey

Generic Country - France, No City Provided, New Jersey

Generic Country - Germany, No City Provided, New Jersey

Generic Country - Italy, No City Provided, New Jersey

Generic Country - UK, No City Provided, New Jersey

Generic Country - USA, No City Provided, New Jersey

Local Institution - 0049, Stony Brook, New York

Local Institute, Cary, North Carolina

Local Institution - 0033, Cary, North Carolina

Local Institution - 0010, Gastonia, North Carolina

Local Institution, Gastonia, North Carolina

Local Institute, Canton, Ohio

Local Institution - 0022, Canton, Ohio

Local Institute, Cleveland, Ohio

Local Institution - 0019, Cleveland, Ohio

Local Institute, Tulsa, Oklahoma

Tulsa Cancer Institute PLLC, Tulsa, Oklahoma

Local Institute, Portland, Oregon

Local Institute, Pottstown, Pennsylvania

Local Institution - 0043, Pottstown, Pennsylvania

Local Institute, Charleston, South Carolina

Local Institution - 0016, Charleston, South Carolina

Local Institute, Knoxville, Tennessee

Local Institution - 0038, Knoxville, Tennessee

Local Institution - 0035, Memphis, Tennessee

Local Institution, Memphis, Tennessee

Local Institute, Amarillo, Texas

Local Institution - 0029, Amarillo, Texas

Local Institution - 0063, Bryan, Texas

Local Institute, Corpus Christi, Texas

Local Institute, Dallas, Texas

Local Institution - 0025, Dallas, Texas

Local Institute, Dallas, Texas

Local Institution - 0014, Dallas, Texas

Local Institution - 0032, Garland, Texas

Local Institute, San Antonio, Texas

Local Institution - 0027, San Antonio, Texas

Local Institute, Sherman, Texas

Local Institution - 0028, Sherman, Texas

Local Institute, Seattle, Washington

Local Institution - 0039, Seattle, Washington

Local Institute, Spokane, Washington

Local Institution - 0026, Spokane, Washington

Local Institute, Yakima, Washington

Local Institution - 0031, Yakima, Washington

Local Institution - 0065, Toronto, Ontario

Local Institute, Toronto, Ontario

Local Institution - 0066, Toronto, Ontario

Local Institute, Weston, Ontario

Local Institute, Blois, Not set

Local Institution - 0106, Cannes Cedex, Not set

Local Institution - 0099, Chalon sur Saone, Not set

Local Institute, Chalon sur Saone, Not set

Local Institute, La Roche sur Yon, Not set

Local Institution - 0100, La Roche-sur-yon Cedex 9, Not set

Local Institution - 0104, Limoges, Not set

Local Institute, Limoges, Not set

Local Institution - 0105, Meaux, Not set

Local Institute, Meaux, Not set

Local Institution - 0102, Nantes, Not set

Local Institute, Nantes, Not set

Local Institution - 0101, Perigueux, Not set

Local Institute, Rennes, Not set

Local Institution - 0103, Rennes, Not set

Local Institute, Heidelberg, Baden-Württemberg

Local Institute, Hamm, Nordrhein-Westfalen

Local Institute, Aschaffenburg, Not set

Local Institution - 0072, Aschaffenburg, Not set

Local Institute, Berlin, Not set

Local Institution - 0068, Berlin, Not set

Local Institution - 0081, Bielefeld, Not set

Local Institution, Bochum, Not set

Local Institute, Dresden, Not set

Local Institution - 0069, Dresden, Not set

Local Institution - 0082, Dresden, Not set

Local Institution - 0077, Frankfurt-oder, Not set

Local Institution - 0084, Gelsenkirchen, Not set

Local Institution - 0089, Goslar, Not set

Local Institution - 0070, Hamm, Not set

Local Institution - 0071, Heidelberg, Not set

Local Institution - 0088, Kiel, Not set

Local Institution - 0087, Köln, Not set

Local Institution - 0076, Ludwigsburg, Not set

Local Institute, Magdeburg, Not set

Local Institution - 0067, Magdeburg, Not set

Local Institution - 0073, Muenchen, Not set

Local Institution - 0079, Mutlangen, Not set

Local Institute, München, Not set

Local Institution - 0080, Oldenburg, Not set

Local Institution - 0075, Reutlingen, Not set

Local Institution - 0074, Rostock, Not set

Local Institution - 0086, Rostock, Not set

Local Institute, Rostock, Not set

Local Institution - 0078, Traunstein, Not set

Local Institution - 0085, Wiesbaden, Not set

Local Institute, Pesaro, Pesaro E Urbino

Local Institute, Ancona, Not set

Local Institution - 0108, Ancona, Not set

Local Institute, Ancona, Not set

Local Institution - 0119, Cagliari, Not set

Local Institute, Cagliari, Not set

Local Institution - 0111, Firenze, Not set

Local Institute, Firenze, Not set

Local Institute, Lecce, Not set

Local Institution - 0113, Lecce, Not set

Local Institution - 0124, Messina, Not set

Local Institution - 0120, Messina, Not set

Local Institute, Milano, Not set

Local Institution - 0116, Milano, Not set

Local Institute, Napoli, Not set

Local Institution - 0114, Napoli, Not set

Local Institution - 0115, Pesaro, Not set

Local Institution - 0121, Pescara, Not set

Local Institute, Roma, Not set

Local Institution - 0109, Roma, Not set

Local Institution - 0110, Roma, Not set

Local Institution - 0118, Roma, Not set

Local Institution, Roma, Not set

Local Institution - 0122, San Giovanni Rotondo (FG), Not set

Local Institution - 0107, Terni, Not set

Local Institute, Terni, Not set

Local Institute, Torino, Not set

Local Institution - 0112, Torino, Not set

Local Institute, Vicenza, Not set

Local Institution - 0117, Vicenza, Not set

Local Institute, Truro, Cornwall

Local Institution - 0098, Harrow, Greater London

Local Institute, Leeds, Not set

Local Institution - 0092, Leeds, Not set

Local Institution - 0091, Liverpool, Not set

Local Institution, Liverpool, Not set

Local Institution - 0097, Manchester, Not set

Local Institute, Nottingham, Not set

Local Institution - 0095, Nottingham, Not set

Local Institute, Stafford, Not set

Local Institution - 0096, Stafford, Not set

Local Institute, Swansea, Not set

Local Institution - 0093, Swansea, Not set

Local Institution - 0094, Truro, Not set

Conditions: Multiple Myeloma

Learn More ›

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

NCT04234022

Recruiting

The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordabl... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/02/2025

Locations: The Royal Wolverhampton NHS Trust, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06399393

Recruiting

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +117 locations

Banner MD Anderson Cancer Center, Gilbert, Arizona

Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona

UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California

University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange, California

University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California

Colorado Blood Cancer Institute, Denver, Colorado

Yale University School of Medicine, New Haven, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

AdventHealth Orlando, Orlando, Florida

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Massachusetts General Hospital, Boston, Massachusetts

Boston Medical Center, Boston, Massachusetts

Local Institution - 0123, Ann Arbor, Michigan

Ascension Providence Hospital, Southfield, Michigan

Local Institution - 0119, Minneapolis, Minnesota

Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Columbia University Irving Medical Center, New York, New York

Novant Health Cancer Institute - Elizabeth, Charlotte, North Carolina

Wake Forest Baptist Health, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

St. David's South Austin Medical Center, Austin, Texas

UT Southwestern Medical Center, Dallas, Texas

Houston Methodist Hospital, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Local Institution - 0136, Richmond, Virginia

Royal Prince Alfred Hospital, Camperdown, New South Wales

Local Institution - 0005, Brisbane, Queensland

Peter MacCallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

St Vincent's Hospital, Melbourne, Victoria

Fiona Stanley Hospital, Murdoch, Western Australia

Uniklinikum Salzburg, Salzburg, Not set

Medizinische Universität Wien, Wien, Not set

Institut Jules Bordet, Anderlecht, Bruxelles-Capitale, Région De

UZ Brussel, Brussels, Bruxelles-Capitale, Région De

Local Institution - 0133, Edmonton, Alberta

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario

Local Institution - 0134, Montreal, Quebec

Local Institution - 0036, Brno, Brno-město

Local Institution - 0034, Hradec Kralove, Hradec Králové

Local Institution - 0035, Olomouc, Olomoucký Kraj

Local Institution - 0033, Praha 2, Not set

Local Institution - 0070, Odense, Syddanmark

CHU Bordeaux Haut-Leveque, Pessac, Aquitaine

Institut Paoli-Calmettes, Marseille, Bouches-du-Rhône

Hopital Claude Huriez - CHU de Lille, Lille, Nord

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes, Pays-de-la-Loire

Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhône

Henri Mondor Hospital, Créteil, Val-de-Marne

Gustave Roussy, Villejuif, Val-de-Marne

Local Institution - 0029, Poitiers, Vienne

Hôpital Saint-Louis, Paris, Not set

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE, Toulouse, Not set

Hôpital Saint Antoine, Paris, Île-de-France

Local Institution - 0072, Heidelberg, Baden-Württemberg

Local Institution - 0078, Ulm, Baden-Württemberg

Local Institution - 0077, Nuremberg, Bayern

Local Institution - 0073, Köln, Nordrhein-Westfalen

Local Institution - 0079, Dresden, Sachsen

Local Institution - 0087, Leipzig, Sachsen

Local Institution - 0075, Kiel, Schleswig-Holstein

Local Institution - 0115, Essen, Not set

Local Institution - 0076, Hamburg, Not set

Local Institution - 0074, Wuerzburg, Not set

University Hospital of Patras, Patras, Achaḯa

Evangelismos General Hospital of Athens, Athens, Attikí

Attikon General University Hospital, Chaidari, Attikí

G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki

Local Institution - 0055, Be'er Sheva, HaDarom

Local Institution - 0058, Petah-Tikva, HaMerkaz

Sheba Medical Center, Ramat Gan, HaMerkaz

Sourasky Medical Center, Tel Aviv, Tell Abīb

Rambam Health Care Campus, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Humanitas, Rozzano, Milano

Local Institution - 0067, Torino, Piemonte

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

AOU Policlinico Umberto I, Roma, Not set

Nagoya City University Hospital, Nagoya, Aichi

Hokkaido University Hospital, Sapporo, Hokkaido

Hyogo Medical University Hospital, Nishinomiya, Hyogo

Kanazawa University Hospital, Kanazawa, Ishikawa

Tokai University Hospital, Isehara, Kanagawa

Chiba University Hospital, Chiba, Not set

Local Institution - 0054, Fukuoka, Not set

Okayama University Hospital, Okayama, Not set

Local Institution - 0071, Shimotsuke, Not set

Local Institution - 0050, Tokyo, Not set

Local Institution - 0041, Hwasun Gun, Jeonranamdo

Local Institution - 0039, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0040, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0038, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0043, Seoul, Seoul-teukbyeolsi [Seoul]

Oslo Universitetssykehus Rikshospitalet, Oslo, Not set

Centrum Onkologii Ziemi Lubelskiej, Lublin, Lubelskie

Samodzielny Publiczny Centralny Szpital Kliniczny w Warszawie, Warsaw, Mazowieckie

Instytut Hematologii i Transfuzjologii, Warsaw, Mazowieckie

Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznań, Not set

Narodowy Instytut Onkologii - Oddzial w Gliwicach, Gliwice, Śląskie

Institutul Clinic Fundeni, Bucharest, Not set

Institut Català d'Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona]

Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet Del Llobregat, Barcelona [Barcelona]

Hospital Clínic de Barcelona, Barcelona, Catalunya [Cataluña]

Clinica Universidad de Navarra, Pamplona, Navarra

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Not set

Hospital Universitari i Politecnic La Fe, València, Not set

Local Institution - 0093, Birmingham, England

Local Institution - 0080, London, London, City Of

Local Institution - 0094, London, London, City Of

Local Institution - 0081, Glasgow, Not set

Conditions: Multiple Myeloma

Learn More ›

Methods of T Cell Depletion Trial (MoTD)

NCT04888741

Recruiting

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Gender:

ALL

Ages:

Between 16 years and 70 years

Trial Updated:

09/25/2023

Locations: University Hospital of Wales, Cardiff, Wales +14 locations

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelofibrosis

Learn More ›

Myeloma Novel Drug Discovery Ver 1.2

NCT05968417

Recruiting

Myeloma is a bone marrow cancer with over 5000 patients diagnosed in the UK each year. Researchers are committed to improving understanding of myeloma and developing more effective treatments with fewer side effects in order to improve patient outcomes. In order to do this, researchers are collecting samples of blood and bone marrow to test the activity of potential new treatments in the laboratory and to understand what may be the cause of some treatments not working.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/01/2023

Locations: The Royal Marsden NHS Foundation Trust, London Borough of Sutton, Not set

Conditions: Multiple Myeloma

Learn More ›

The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

NCT03562169

Recruiting

Study design: Randomised, controlled, multi-centre, open-label, phase III trial (with a single intervention registration phase). Primary Objectives The primary objectives of this study are to determine: * The impact on Depth of Response (DoR: less than VGPR versus VGPR or better) when salvage ASCT conditioning is augmented by the addition of a proteasome inhibitor * The influence of a consolidation and maintenance strategy on the Durability of Response (DuR:PFS) Secondary objectives The secondary objectives of this study are to determine: * Overall survival * Time to disease progression * The overall response rate following ixazomib, thalidomide and dexamethasone (ITD) re-induction * Time to next treatment * Progression-free survival 2 (PFS2) * Duration of response * Minimal Residual Disease (MRD) negative rate post re-induction, post-ASCT and conversion after ITD consolidation * Engraftment kinetics * Toxicity and safety * Quality of life (QoL) Participant population (refer to protocol section 9 for a full list of eligibility criteria). * Relapsed MM (with measurable disease by IMWG criteria) previously treated with ASCT * First progressive disease (PD) at least 12 months since first ASCT, requiring therapy. * ECOG Performance Status 0-2 * Aged at least 18 years * Adequate full blood count and renal, hepatobiliary, pulmonary and cardiac function * Written informed consent Interventions: All participants will be registered at trial entry and will receive re-induction therapy with 4-6, 28-day cycles of ixazomib, thalidomide and dexamethasone (ITD), in order to reach maximum response. Participants who achieve at least stable disease (SD) will be randomised on a 1:1 basis to receive either conventional ASCT (ASCTCon), using melphalan, or augmented ASCT (ASCTAug), using melphalan with ixazomib. All participants achieving or maintaining a minimal response (MR) or better following trial ASCT will undergo a second randomisation to consolidation and maintenance or no further treatment. Participants randomised to consolidation and maintenance will receive treatment as follows: consolidation with 2 cycles of ITD and maintenance with ixazomib until disease progression. Number of participants: 406 participants will be registered into the trial to allow 284 participants to be randomised at the first randomisation (R1) and 248 participants to be randomised at the second randomisation (R2). Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2018

Locations: Aberdeen Royal Infirmary, Aberdeen, Not set +90 locations

Aberdeen Royal Infirmary, Aberdeen, Not set

Monklands Hospital, Airdrie, Not set

University Hospital Ayr, Ayr, Not set

Barnsley Hospital, Barnsley, Not set

Basingstoke & North Hampshire Hospital, Basingstoke, Not set

Royal United Hospital, Bath, Not set

Good Hope Hospital, Birmingham, Not set

Heartlands Hospital, Birmingham, Not set

Queen Elizabeth Hospital, Birmingham, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Pilgrim Hospital, Boston, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Bradford Royal Infirmary, Bradford, Not set

Bristol Haematology & Oncology Centre, Bristol, Not set

Southmead Hospital, Bristol, Not set

Queen's Hospital, Burton Upon Trent, Not set

Addenbrooke's Hospital, Cambridge, Not set

St Helier Hospital, Carshalton, Not set

Cheltenham General Hospial, Cheltenham, Not set

Chesterfield Royal Hospital, Chesterfield, Not set

Countess of Chester Hospital, Chester, Not set

St Richards Hospital, Chichester, Not set

University Hospital Coventry, Coventry, Not set

Royal Derby Hospital, Derby, Not set

Dewsbury Hospital, Dewsbury, Not set

Russells Hall Hospital, Dudley, Not set

Ninewells Hospital, Dundee, Not set

Hairmyres Hospital, East Kilbride, Not set

Western General Hospital, Edinburgh, Not set

Beatson Cancer Centre, Glasgow, Not set

New Victoria Hospital, Glasgow, Not set

Gloucestershire Royal Hospital, Gloucester, Not set

Grantham and District Hospital, Grantham, Not set

Diana Princess of Wales Hospital, Grimsby, Not set

Calderdale Royal Hospital, Halifax, Not set

Harrogate District Hospital, Harrogate, Not set

Huddersfield Royal Infirmary, Huddersfield, Not set

Castle Hill Hospital, Hull, Not set

Raigmore Hospital, Inverness, Not set

Ipswich Hospital, Ipswich, Not set

Kidderminster Hospital, Kidderminster, Not set

University Hospital Crosshouse, Kilmarnock, Not set

St James's University Hospital, Leeds, Not set

Leicester Royal Infirmary, Leicester, Not set

Lincoln County Hospital, Lincoln, Not set

Royal Liverpool University Hospital, Liverpool, Not set

University Hospital Aintree, Liverpool, Not set

Guys and St Thomas's Hospital, London, Not set

Kings College Hospital, London, Not set

Royal Marsden Hospital, London, Not set

St Barts Hospital, London, Not set

University College London Hospital, London, Not set

Maidstone Hospital, Maidstone, Not set

Manchester Royal Infirmary, Manchester, Not set

The Christie, Manchester, Not set

Borders General Hospital, Melrose, Not set

James Cook University Hospital, Middlesbrough, Not set

Milton Keynes General Hospital, Milton Keynes, Not set

Freeman Hospital, Newcastle, Not set

North Tyneside General Hospital, North Shields, Not set

Norfolk & Norwich University Hospital, Norwich, Not set

Nottingham City Hospital, Nottingham, Not set

Royal Oldham Hospital, Oldham, Not set

Churchill Hospital, Oxford, Not set

Royal Alexandra Hospital, Paisley, Not set

Derriford Hospital, Plymouth, Not set

Pontefract Hospital, Pontefract, Not set

Whiston Hospital, Prescot, Not set

Royal Berkshire Hospital, Reading, Not set

Redditch Hospital, Redditch, Not set

Salford Royal Hospital, Salford, Not set

Salisbury Hospital, Salisbury, Not set

Scunthorpe General Hospital, Scunthorpe, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

St Helens Hospital, St Helens, Not set

Stafford County Hospital, Stafford, Not set

Stepping Hill Hospital, Stockport, Not set

Royal Stoke University Hospital, Stoke-on-Trent, Not set

Sunderland Royal Hospital, Sunderland, Not set

King's Mill Hospital, Sutton In Ashfield, Not set

Singleton Hospital, Swansea, Not set

Musgrove Park Hospital, Taunton, Not set

St George's Hospital, Tooting, Not set

Tunbridge Wells Hospital, Tunbridge Wells, Not set

Pinderfields General Hospital, Wakefield, Not set

Royal Hampshire County Hospital, Winchester, Not set

Wishaw Hospital, Wishaw, Not set

New Cross Hospital, Wolverhampton, Not set

Worcestershire Royal Hospital, Worcester, Not set

Worthing Hospital, Worthing, Not set

Conditions: Multiple Myeloma

Learn More ›

13 - 23 of 23